Study details
Enrolling now
Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD) and/or Other Substance Use Disorders (SUDs)
InSightec
NCT IDNCT04197921ClinicalTrials.gov data as of Apr 2026
Target enrollment
29
Study length
about 7.1 years
Ages
18–60
Locations
4 sites in FL, MD, NY +1
What this study is about
This trial is testing a device called Exablate Model 4000 Type 2.0/2.1, used with Low Intensity Focused Ultrasound (LIFU), as an additional treatment for Opioid Use Disorder (OUD) and other substance use disorders. The goal is to see if this device is safe and well-tolerated in people with OUD.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Use Exablate Model 4000 Type 2.0/2.1
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Occurrence of Treatment Emergent Adverse Events
Body systems
Psychiatry / Mental Health